Skip to Content

ELAD Study


Principal Investigator:

Dr Bernadette McGuinness


Name of the study:

Evaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients with Alzheimer’s Disease. (ELAD)


Aim of the research:

This study will test whether the currently available new treatment for diabetes will be effective for Alzheimer's disease. Participants will be helping to test a drug called Liraglutide in Alzheimer’s disease as a potential future treatment.


Background to the research:

We are carrying out a study to test the effect of a drug that is already used for the treatment of diabetes, in AD. Laboratory studies have shown this drug could be effective.


What the study involves:

At the beginning of the study, participants will have a detailed medical examination along with memory testing and blood test. Then they will have an MRI scan and a special brain scan using PET/CT scanner to look at the brain function.

A subgroup of people will have another PET/CT scan (optional) to look at brain inflammation. The brain scan will be performed at the start of the study and again after 12 months.

Participants will have regular visits to their local study sites.


Who can take part in the study: 

We are looking for people who have early or mild Alzheimer’s disease. This study will be conducted in centers throughout the UK.



12 month, multi-centre, randomised, double blind, placebo controlled study in patients with mild Alzheimer’s Disease. Visits include physical, neurological and cognitive assessments in the Belfast City Hospital Clinical Research Facility. Participants and study partner attend Imperial College

London for scans at the beginning and end of the study.

If you think you might be suitable and would be interested in taking part, please use the contact information below.


Contact Information For Dr Bernadette McGuinness


Phone: 02890978969 / 02890978970



NI Clinical Research Facility,
U Floor, Belfast City Hospital,
Lisburn Road, Belfast, BT9 7AB

Tel:+44 (0)28 9504 0342

Connect to the NICRF